PVLA PALVELLA THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1583648 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-113.9%
TTM EPS YoY-120.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-63.4%
ROA-49.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets17.3%
Debt / equity0.00x
Current ratio16.01x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.57x
Accruals ratio-20.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | $42.81M | $25.90M | $31.42M |
| R&D expense | $22.84M | $8.15M | $8.79M | $52.98M | $66.66M |
| SG&A expense | $15.76M | $5.94M | $3.08M | $16.39M | $16.59M |
| Operating income | -$38.60M | -$14.10M | -$11.87M | -$43.47M | -$51.83M |
| Interest expense | $0 | $430,000 | $0 | — | — |
| Pretax income | -$41.72M | -$17.43M | $18.69M | -$33.28M | -$45.74M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$41.72M | -$17.43M | $18.69M | -$33.28M | -$45.74M |
| EBITDA | — | — | -$9.96M | -$40.70M | -$49.37M |
| EPS (basic) | -3.71 | -7.83 | 2.19 | -0.45 | -0.71 |
| EPS (diluted) | -3.71 | -7.83 | 2.17 | — | -0.71 |
| Weighted avg. shares (diluted) | 11.25M | 2.23M | 1.79M | — | 64.55M |
| Banking | |||||
| Net interest income | $2.59M | $642,000 | — | — | — |
| Balance sheet | |||||
| Cash & equivalents | $57.98M | $83.60M | $7.35M | $38.63M | $117.76M |
| Short-term investments | $0 | — | $8.97M | $20.53M | $0 |
| Receivables | $0 | $358,000 | $0 | $5.81M | $3.31M |
| Current assets | $58.99M | $88.23M | $7.55M | $73.42M | $127.62M |
| PP&E, net | — | — | $0 | $16.99M | $19.12M |
| Total assets | $59.56M | $88.23M | $7.55M | $95.49M | $153.56M |
| Current liabilities | $11.34M | $12.04M | $2.36M | $36.58M | $50.56M |
| Total liabilities | $31.58M | $25.63M | $11.43M | $67.56M | $102.81M |
| Shareholders' equity | $27.98M | $62.61M | -$74.48M | -$93.78M | $50.76M |
| Shares outstanding | 12.38M | 11.01M | 1.77M | 74.52M | 72.22M |
| Cash flow statement | |||||
| Operating cash flow | -$25.01M | -$10.84M | -$13.70M | -$59.93M | -$7.66M |
| Capital expenditure | — | — | $171,000 | $1.04M | $949,000 |
| Free cash flow | — | — | -$13.87M | -$60.97M | -$8.61M |
| Investing cash flow | — | — | $12.00M | -$21.24M | -$949,000 |
| Financing cash flow | -$660,000 | $87.09M | $5.00M | $7.21M | $59.13M |
| Depreciation & amortization | — | — | $1.90M | $2.77M | $2.46M |
| Stock-based compensation | $6.40M | $830,000 | $603,000 | $4.40M | $5.21M |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.